{"id":"W4306739715","doi":"10.1016/j.breast.2022.10.007","title":"Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer","year":2022,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"EMD Serono; Genentech; PharmaMar; G1 Therapeutics; MacroGenics; Pfizer; Incyte; NuCana; Seagen; Relay Therapeutics; Plexxikon; Ontario Brain Institute; Syndax Pharmaceuticals; Regeneron Pharmaceuticals; Amgen; Radius Health; Gilead Sciences; Merck; Mersana Therapeutics; Novartis; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Roche; Astellas Pharma US","keywords":"Medicine; Metastatic breast cancer; Antibody-drug conjugate; Drug; Cancer; Antibody; Breast cancer; Oncology; Conjugate; Drug development; Cancer research; Internal medicine; Pharmacology; Immunology; Monoclonal antibody","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00319642,0.000187582,0.0004496949,0.0001247793,0.0003057956,0.00002929089,0.0003933816,0.00002587067,0.003992179],"category_scores_gemma":[0.0000819266,0.0001323122,0.000101671,0.0005288474,0.0001984994,0.00005285258,0.000405596,0.0009591613,0.0001014099],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004929556,"about_ca_system_score_gemma":0.001212185,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001266238,"about_ca_topic_score_gemma":0.0001942496,"domain_scores_codex":[0.9969601,0.0006160837,0.0006038456,0.0003975462,0.0008261753,0.0005962183],"domain_scores_gemma":[0.9989088,0.0003095562,0.0001219215,0.0003708698,0.00009817028,0.0001906448],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001885627,0.001116414,0.8314654,0.0003302835,0.0004281122,0.0005576372,0.003750097,0.0003409297,0.004863751,0.0002510817,0.01624137,0.1387694],"study_design_scores_gemma":[0.005201558,0.0002027117,0.8857522,0.0004175714,0.0001365137,0.002466485,0.004223962,0.001751037,0.0006309401,0.0001261147,0.09859248,0.0004984242],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9733452,0.00163657,0.00002888856,0.02217747,0.0004260775,0.0008752143,0.0001923018,0.00007500453,0.001243321],"genre_scores_gemma":[0.996557,0.0001800972,0.000446612,0.0009842545,0.0002818611,0.000299825,0.00008478352,0.00005082754,0.001114763],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1382709,"threshold_uncertainty_score":0.9969183,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05927251587468007,"score_gpt":0.4248498023256788,"score_spread":0.3655772864509987,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}